Images in Haematology
Charcot-Leyden crystals in the trephine biopsy of a patient with a FIP1L1-PDGFRA– positive myeloproliferative disorder
Hamish Lyall, Simon O'Connor and David Clark
p. 405–405
Atypical presentation of varicella zoster in a patient on alemtuzumab
Suresh Venkatachalapathy, Josephine Crowe and Atherton Gray
p. 406–406
Reviews
Light and shadows in the iron chelation treatment of haematological diseases
Aurelio Maggio
p. 407–421
Management of cold haemolytic syndrome
Morie A. Gertz
p. 422–429
Thrombosis and acute lymphoblastic leukaemia
Jeanette H. Payne and Ajay J. Vora
p. 430–445
Haematological Malignancy
Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK
Monica Hecht, Ulrike Heider, Martin Kaiser, Ivana von Metzler, Jan Sterz and Orhan Sezer
p. 446–458
Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction
Christine Damm-Welk, Jutta Schieferstein, Simone Schwalm, Alfred Reiter and Willi Woessmann
p. 459–466
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid
Richard A. Campbell Eric Sanchez Jeffrey A. Steinberg Stavroula Baritaki Melinda Gordon Cathy Wang Dror Shalitin Haiming Chen Shen Pang Benjamin Bonavida Jonathan Said and James R. Berenson
p. 467–478
MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas
Amanda P. Liggins, Christopher D. O. Cooper, Charles H. Lawrie, Philip J. Brown, Graham P. Collins, Chris S. Hatton, Karen Pulford and Alison H. Banham
p. 479–486
In primary effusion lymphoma cells, MYB transcriptional repression is associated with v-FLIP expression during latent KSHV infection while both v-FLIP and v-GPCR become involved during the lytic cycle
Vincent Lacoste, Christophe Nicot, Antoine Gessain, Françoise Valensi, Jean Gabarre, Hittu Matta, Preet M. Chaudhary and Renaud Mahieux
p. 487–501
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
Nam H. Dang, Luis Fayad, Peter McLaughlin, Jorge E. Romaguara, Fredrick Hagemeister, Andre Goy, Sattva Neelapu, Felipe Samaniego, Pamela L. Walker, Michael Wang, Maria A. Rodriguez, Ann T. Tong and Barbara Pro
p. 502–505
Paediatric
Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report
Rodney R. Miles, Mitchell S. Cairo, Prakash Satwani, David L. Zwick, Mark A. Lones, Richard Sposto, Minnie Abromovitch, Sheryl Tripp, Anne L. Angiolillo, Elizabeth Roman, Virginia Davenport and Sherrie L. Perkins
p. 506–512
A clinical score predicting a brief and uneventful course of newly diagnosed idiopathic trombocytopenic purpura in children
Pernille Wendtland Edslev, Steen Rosthøj, Iris Treutiger, Jukka Rajantie, Bernward Zeller and Olafur G. Jonsson on behalf of the NOPHO ITP Working Group
p. 513–516
Transplantation
Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes
Zi Yi Lim, Laurence Pearce, Aloysius Y. Ho, Linda Barber, Wendy Ingram, Monica Usai, Khalid Tobal, Stephen Devereux, Antonio Pagliuca and Ghulam J. Mufti
p. 517–526
Platelets,Haemostasis and Thrombosis
Microparticles adhere to collagen type I, fibrinogen, von Willebrand factor and surface immobilised platelets at physiological shear rates
J. F. W. Keuren, E. J. P Magdeleyns, A. Bennaghmouch, E. M. Bevers, J. Curvers and T. Lindhout
p. 527–533
ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis
Hendrik B. Feys, Maria T. Canciani, Flora Peyvandi, Hans Deckmyn, Karen Vanhoorelbeke and Pier M. Mannucci
p. 534–540
Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients
Shrimati Shetty, Sonal Vora, Bipin Kulkarni, Leenam Mota, Manasi Vijapurkar, Leera Quadros and Kanjaksha Ghosh
p. 541–544
Haemopoiesis and Thrombosis
Viscum album agglutinin-I induces degradation of cytoskeletal proteins in leukaemia PLB-985 cells differentiated toward neutrophils: cleavage of non-muscle myosin heavy chain-IIA by caspases
Valérie Lavastre, François Binet, Éliane Moisan, Sonia Chiasson and Denis Girard
p. 545–554
Correspondence
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome
Masamitsu Yanada, Xuelin Huang, Guillermo Garcia-Manero, Susan O'Brien, Farhad Ravandi, Gautam Borthakur, Stefan Faderl, Jean-Pierre Issa, Hagop Kantarjian and Elihu Estey
p. 555–557
Previous fetal loss significantly increases the risk of pre-partal deep-vein thrombosis
K. Ghosh, S. Vora and S. Shetty
p. 557–557
Could rhG-CSF induction of tetraploidy contribute to leukemogenesis in healthy donors?
C. Kaplinsky, L. Trakhtenbrot and S. Izraeli
p. 558–558
The development of sarcoidosis with the use of alemtuzumab – clues to T-cell immune reconstitution
Jecko Thachil, Vittal Jadhav, Manish Gautam, Steve Mckew, Arvind Arumainathan, Daniel Collins, Colin Smyth, Janice Harper and Andrew Pettitt
p. 559–560
|
